Please login to the form below

Not currently logged in
Email:
Password:

Hospira

This page shows the latest Hospira news and features for those working in and with pharma, biotech and healthcare.

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Pfizer could raise ‘up to $15bn’ from consumer unit sale

of failed merger attempts with AstraZeneca and Allergan, the takeovers of Hospira and cancer specialist Medivation, and the divestment of Hospira’s infusions unit.

Latest news

More from news
Approximately 12 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    These two biosimilars were originally licensed by Hospira but when Pfizer acquired Hospira it terminated the agreement. ... For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Pharma deals in February 2015 Pharma deals in February 2015

    There are no approved biosimilars in the US where Hospira awaits approval of Remicade and Retacrit. ... No doubt Pfizer had hoped Hospira's persistent manufacturing problems were a thing of the past.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Medius Deal Watch table for February 2015. The top major pharma mergers, acquisitions and collaborations during the month were led by the Pfizer/Hospira and Salix/Valeant deals. ... Majority acquisition. 380. Pfenex/ Hospira. PF582 - LUCENTIS biosimilar

  • Pharma deals during December 2014 Pharma deals during December 2014

    Acquisitions are frequently complicated by external factors and a day after the Merck acquisition was announced Cubist lost its Cubicin patent infringement lawsuit against Hospira in the US. ... One patent was upheld, which means that Hospira is barred

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    Physicians predict a four-fold increase in their use of Hospira’ s Inflectra and Celltrion’ s Remsima.

  • Infographic: RA Perceptions

    Physicians predict a four-fold increase in their use of Hospira’ s Inflectra and Celltrion’ s Remsima.

  • FCB Halesway

    Pain relief. Hospira. Anaemia. Neutropenia. Rheumatology. Dermatology. Gastroenterology. Lincoln Medical. Anaphylaxis.

  • Swordfish Advertising

    Genzyme. Undisclosed brands. Hospira. Nipent. Plum-A. Gemstar. Clave. Lifeshield TKO. Vitiq.

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics